This paper is in the following e-collection/theme issue:

Connected Health Conference Abstracts (2019) (34)

Published on in Vol 5, No 1 (2019): CHC19

A Predictive Model for Clinical Asthma Exacerbations Using Albuterol eMDPI (ProAir Digihaler): A Twelve-Week, Open-Label Study

A Predictive Model for Clinical Asthma Exacerbations Using Albuterol eMDPI (ProAir Digihaler): A Twelve-Week, Open-Label Study

A Predictive Model for Clinical Asthma Exacerbations Using Albuterol eMDPI (ProAir Digihaler): A Twelve-Week, Open-Label Study

Authors of this article:

Guilherme Safioti1 ;   Lena Granovsky2 ;   Thomas Li3 ;   Michael Reich2 ;   Shahar Cohen4 ;   Yonatan Hadar4 ;   Roy Pleasants5 ;   Henry Chrystyn6 ;   Tanisha Hill3 ;   Michael DePietro3
Article Authors Cited by (2) Tweetations Metrics

Guilherme Safioti   1 † , MD ;   Lena Granovsky   2 † , PhD ;   Thomas Li   3 † , PhD ;   Michael Reich   2 † , PhD ;   Shahar Cohen   4 † , PhD ;   Yonatan Hadar   4 † , MSc ;   Roy Pleasants   5 † , PharmD ;   Henry Chrystyn   6 † , MPharm, PhD ;   Tanisha Hill   3 † , PhD ;   Michael DePietro   3 † , MD

1 Teva Pharmaceutical Industries, Amsterdam, Netherlands

2 Teva Pharmaceuticals, Petah Tikva, Israel

3 Teva Branded Pharmaceuticals R&D Inc., Malvern, PA, United States

4 Yellow Road, Petah Tikva, Israel

5 University of North Carolina, School of Medicine, Division of Pulmonary Medicine and Critical Care, Chapel Hill, NC, United States

6 Inhalation Consultancy Ltd, Leeds, United Kingdom

Corresponding Author: